CD274 and non-small cell lung carcinoma: Moreover, none of these studies have attempted to systematically employ and compare a wide range of feature selection and machine learning methodologies for the prediction of PD-L1 and PFS (short-term vs. long-term survivors) in patients with advanced NSCLC treated with immunotherapy from a multicenter perspective using a large cohort of patients.